BD announced a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash, expanding BD's portfolio of smart connected care solutions.

BD's 2025 strategy focuses on growth through research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs, while improving operating efficiency and organizational effectiveness.

BD continues to pursue growth opportunities in emerging markets, including EMA, Latin America, and certain countries within Greater Asia.

BD is focused on reducing complexity, optimizing supply chain efficiency, streamlining global manufacturing footprint, enhancing product quality, refining customer experience, and improving cost efficiency across all segments.

BD is leveraging procurement, logistics, and manufacturing capabilities to mitigate impacts of macroeconomic factors, but there is no assurance that these strategies will be effective.

BD incurred restructuring costs during the nine months ended June 30, 2024, primarily in connection with the Company's simplification and other cost-saving initiatives.

BD's operations are exposed to various global macroeconomic factors, including market dynamics in China, labor costs, supply chain disruptions, and geopolitical conditions.

Increased regulatory focus on ethylene oxide use and emissions could require BD to suspend operations, limit use, or take other actions, impacting operations and increasing costs.

BD's infusion pump business is operating under an amended consent decree with the FDA, which could result in penalties and other actions if violations occur.

BD experienced strong global demand for the Medication Delivery Solutions unit's Vascular Access Management portfolio, as well as strong U.S. demand for hypodermic products, and double-digit growth in sales of infusion systems.

Market dynamics in China, such as volume-based procurement programs, had an adverse impact on BD's results of operations.

BD faces competitive factors, including new product introductions, consolidation among healthcare companies, and increased pricing pressure from low-cost manufacturers.

BD is focused on continuous improvement projects and other productivity initiatives to lower manufacturing costs.

BD continues to experience temporary shortages in supply of certain materials or components, and events affecting global logistics may adversely impact the supply chain.

Lower selling and administrative expenses as a percentage of revenues in the third quarter of 2024 compared with the third quarter of 2023 primarily reflected cost containment measures and lower shipping costs.

BD continues to invest in research and development to drive further revenue and profit growth.

The acquisition of Edwards Lifesciences' Critical Care product group will expand BD's portfolio of smart connected care solutions.

BD continues to develop new products and technologies, but faces difficulties inherent in product development, including obtaining regulatory approvals and maintaining intellectual property protection.

BD issued $600 million and €1.000 billion in notes in June 2024 to fund the acquisition of Edwards Lifesciences' Critical Care product group.

BD repurchased 1.541 million shares of its common stock during the quarter ended June 30, 2024.

BD paid cash dividends to common shareholders of $825 million during the first nine months of fiscal year 2024.

BD has proactively installed fugitive emissions controls at its facilities and is working to comply with new regulations regarding ethylene oxide emissions.

BD entered into a consent order with the Environmental Protection Division of the Georgia Department of Natural Resources and is working to comply with the terms of the order.

BD is focused on sustainability and is working to address climate change, including regulation of greenhouse gas emissions and changing customer preferences.

BD's operations are exposed to various global macroeconomic factors, including market dynamics in China, labor costs, supply chain disruptions, and geopolitical conditions.

Cost-containment efforts in the U.S. and other countries, such as alternative payment reform and increased use of competitive bidding, could impact BD's operations.

Changes in the way healthcare services are delivered, including transition of more care from acute to non-acute settings, may affect the demand for BD's products and services.